Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 5:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1873–1896 of 5,061 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Capsule 2 Clear all
Completed Phase 3 Interventional Results available

A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT01578707
View directory record Official record
Conditions
Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
ofatumumab, ibrutinib
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
25
States / cities
La Jolla, California • Los Angeles, California • Santa Maria, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Nov 12, 2026, 5:45 PM EST
Completed Phase 1 Interventional

Effects of Sage on Memory and Mental Performance in Alzheimer's Disease Patients

NCT00110552
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Salvia officinalis (sage)
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
50 Years to 90 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 29, 2014 · Synced Nov 12, 2026, 5:45 PM EST
Completed Phase 3 Interventional Results available

A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)

NCT00943111
View directory record Official record
Conditions
Gaucher Disease, Type 1
Interventions
Eliglustat tartrate, Imiglucerase
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
17
States / cities
Beverly Hills, California • San Francisco, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2016 · Synced Nov 12, 2026, 5:45 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of SSP-004184 (FBS0701) in Healthy Adults and Elderly Subjects and in Subjects With Impaired Renal Function

NCT01716455
View directory record Official record
Conditions
Impaired Renal Function
Interventions
SSP-004184
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 85 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Nov 12, 2026, 5:45 PM EST
Completed Phase 2 Interventional Results available

Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria

NCT02289755
View directory record Official record
Conditions
Hyperoxaluria, Nephrolithiasis
Interventions
ALLN-177
Drug
Lead sponsor
Allena Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Indianapolis, Indiana • Lake Success, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Nov 12, 2026, 5:45 PM EST
Terminated Phase 1 Interventional Results available

A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

NCT05556616
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Modakafusp alfa, Lenalidomide, Bortezomib, Carfilzomib, Daratumumab, Pomalidomide
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
14
States / cities
Sacramento, California • San Diego, California • Iowa City, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Nov 12, 2026, 5:45 PM EST
Completed Phase 4 Interventional Results available

A Multi-level Life-span Characterization of Adult-depression and Effects of Medication and Exercise

NCT02407704
View directory record Official record
Conditions
Depression, Depressive Disorder, Major, Depressive Disorder, Unipolar Depression, Major Depressive Disorder
Interventions
Venlafaxine XR, Aerobic Exercise, Lorazepam
Drug · Other
Lead sponsor
Kirk Erickson, PhD
Other
Eligibility
60 Years to 79 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Nov 12, 2026, 5:45 PM EST
Terminated Phase 1 Interventional

Sildenafil and Stroke Recovery

NCT02628847
View directory record Official record
Conditions
Stroke
Interventions
sildenafil citrate, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Nov 12, 2026, 5:45 PM EST
Completed Phase 4 Interventional Results available

Study of Oral Treatments for Hepatitis C

NCT02786537
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
SOF/LDV (sofosbuvir/ledipasvir), PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only), EBR/GZR (elbasvir/grazoprevir), Ribavirin
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
1,275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
38
States / cities
Little Rock, Arkansas • Palo Alto, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Nov 12, 2026, 5:45 PM EST
Completed Phase 4 Interventional Results available

A Phase IV Safety and Efficacy Study of VI-0521 in Adolescents With Obesity

NCT03922945
View directory record Official record
Conditions
Adolescent Obesity, Obesity in Adolescence, Adolescent Overweight
Interventions
VI-0521 oral capsule, Placebo oral capsule, Lifestyle Modification
Drug · Behavioral
Lead sponsor
VIVUS LLC
Industry
Eligibility
12 Years to 16 Years
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Norman, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 10, 2022 · Synced Nov 12, 2026, 5:45 PM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)

NCT01259492
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Placebo, Ritalin LA 20 mg, Ritalin LA 30 mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
21
States / cities
Little Rock, Arkansas • Beverly Hills, California • Spring Valley, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Nov 12, 2026, 5:45 PM EST
Active, not recruiting Phase 2 Interventional

Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer

NCT04837209
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer
Interventions
Niraparib, Dostarlimab, Radiation therapy
Drug · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Nov 12, 2026, 5:45 PM EST
Completed Phase 2 Interventional

COMT Inhibition Among Individuals With Comorbid AUD/ADHD

NCT03904498
View directory record Official record
Conditions
Alcohol Use Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Tolcapone, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Nov 12, 2026, 5:45 PM EST
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT01349049
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
PLX3397
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
9
States / cities
San Francisco, California • Chicago, Illinois • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Nov 12, 2026, 5:45 PM EST
Completed Phase 1 Interventional Results available

Oral Administration of STC-15 in Subjects With Advanced Malignancies

NCT05584111
View directory record Official record
Conditions
Advanced Cancer, Advanced Solid Tumor, Cancer
Interventions
STC-15
Drug
Lead sponsor
STORM Therapeutics LTD
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Scottsdale, Arizona • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 12, 2026, 5:45 PM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)

NCT06500793
View directory record Official record
Conditions
Pharmacokinetics, Healthy Volunteer
Interventions
PF614 capsule, Nafamostat Mesylate
Drug
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Nov 12, 2026, 5:45 PM EST
Not listed Phase 3 Interventional

Probiotics and Recovery From Gastrointestinal Surgery - 2

NCT04266106
View directory record Official record
Conditions
Surgical Recovery
Interventions
SuperBio probiotic, Placebo
Drug
Lead sponsor
Jan Franko, MD
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Des Moines, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 13, 2020 · Synced Nov 12, 2026, 5:45 PM EST
Recruiting Phase 1 Interventional

A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases

NCT06136884
View directory record Official record
Conditions
Solid Tumor Malignancies, Brain Metastases From Solid Tumors
Interventions
AO-252
Drug
Lead sponsor
A2A Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
6
States / cities
Detroit, Michigan • Oklahoma City, Oklahoma • Charleston, South Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Nov 12, 2026, 5:45 PM EST
Completed Phase 2 Interventional Results available

Duloxetine Versus Pregabalin for Alcohol Dependence

NCT00929344
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Pregabalin, Duloxetine, Standardized behavioral therapy, Placebo
Drug · Behavioral
Lead sponsor
The Scripps Research Institute
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Nov 12, 2026, 5:45 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Vitamin E on Non-Alcoholic Fatty Liver Disease

NCT02690792
View directory record Official record
Conditions
Healthy, NAFLD (Non-Alcoholic Fatty Liver Disease), NASH (Non-Alcoholic Steatohepatitis)
Interventions
NAFLD/NASH - Placebo, NAFLD/NASH - Vitamin E
Other · Dietary Supplement
Lead sponsor
Jeffrey Browning
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Nov 12, 2026, 5:45 PM EST
Completed Phase 2 Interventional Results available

Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation

NCT00135798
View directory record Official record
Conditions
Hepatitis C
Interventions
LADR Treatment
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2013 · Synced Nov 12, 2026, 5:45 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 on the Single-Dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants

NCT04121078
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-906, Rifampin
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Nov 12, 2026, 5:45 PM EST
Recruiting Phase 1Phase 2 Interventional

Rescue Pharmacotherapy for OSA

NCT05293600
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Placebo, Acetazolamide, Trazodone, Atomoxetine and eszopiclone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Nov 12, 2026, 5:45 PM EST
Completed Phase 4 Interventional Results available

Minocycline Augmentation to Clozapine

NCT02124811
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Minocycline
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Nov 12, 2026, 5:45 PM EST